The estimated Net Worth of Holdings (Private) Ltd Full... is at least 43.1 百万$ dollars as of 16 October 2019. Holdings Full owns over 500,000 units of Vir Biotechnology Inc stock worth over 43,064,992$ and over the last 7 years Holdings sold VIR stock worth over 0$.
Sign up
Holdings Full VIR stock SEC Form 4 insiders trading
Holdings has made over 2 trades of the Vir Biotechnology Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Holdings bought 500,000 units of VIR stock worth 10,000,000$ on 16 October 2019.
The largest trade Holdings's ever made was buying 625,000 units of Vir Biotechnology Inc stock on 2 April 2018 worth over 10,000,000$. On average, Holdings trades about 562,500 units every 281 days since 2018. As of 16 October 2019 Holdings still owns at least 5,499,999 units of Vir Biotechnology Inc stock.
You can see the complete history of Holdings Full stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Holdings Full's mailing address?
Holdings's mailing address filed with the SEC is 60A Orchard Rd, Singapore 238890.
Insiders trading at Vir Biotechnology Inc
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over 197,171,926$ worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth 139,246,875$ . The most active insiders traders include Norbert W Bischofberger、Endurance (Cayman) Ltd Sb I...、Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of 478,115$. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth 95,082$.
What does Vir Biotechnology Inc do?
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
What does Vir Biotechnology Inc's logo look like?
Complete history of Holdings Full stock trades at Homology Medicines Inc、Vir Biotechnology Inc
Vir Biotechnology Inc executives and stock owners
Vir Biotechnology Inc executives and other stock owners filed with the SEC include:
-
George Scangos,
President, Chief Executive Officer, Director -
Howard Horn,
Chief Financial Officer, Secretary -
Herbert Virgin,
Executive Vice President of Research and Chief Scientific Officer -
Vicki Sato,
Independent Chairman of the Board -
Dr. Herbert W. Virgin IV, M.D., Ph.D.,
Exec. VP of Research & Chief Scientific Officer -
Dr. Herbert W. Virgin IV,
Exec. VP of Research & Chief Scientific Officer -
Dr. George A. Scangos Ph.D.,
Pres, CEO & Director -
Dr. Ann M. Hanly Ph.D.,
Exec. VP & Chief Technology Officer -
Phil Pang,
Chief Medical Officer -
Dr. George A. Scangos,
Pres, CEO & Director -
Dr. Phillip Pang M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Steven J. Rice,
Chief Admin. Officer -
Saira Ramasastry,
Independent Director -
Robert Perez,
Independent Director -
Phillip Sharp,
Independent Director -
Dr. Klaus Frueh,
Co-Founder & Scientific Advisor -
Robert More,
Independent Director -
Dipchand Nishar,
Independent Director -
Robert Nelsen,
Independent Director -
Elliott Sigal,
Independent Director -
Janet Napolitano,
Director -
Michael Kamarck,
Chief Technology Officer -
Jay Parrish,
Chief Business Officer -
Johanna Friedl-Naderer,
Exec. VP & COO -
Irene Pleasure J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Heather Rowe Armstrong,
VP of Investor Relations -
Dr. Aine M. Hanly Ph.D.,
Chief Technology Officer -
Dr. Louis J. Picker M.D.,
Co-Founder & Scientific Advisor -
Dr. Klaus Frueh Ph.D.,
Co-Founder & Scientific Advisor -
Dr. Neera Dahiya Ravindran M.D., MBA,
VP and Head of Investor Relations & Strategic Communications -
Dr. Louis J. Picker,
Co-Founder & Scientific Advisor -
Dr. Lawrence Corey,
Co-Founder & Scientific Advisor -
Permanent Fund Corp Alaska,
-
& Melinda Gates Foundation ...,
-
Johanna Friedl Naderer,
EVP & Chief Operating Officer -
Steven J. Rice,
Chief Administrative Officer -
Venture Partners Ix, Llcarc...,
-
Endurance (Cayman) Ltd Sb I...,
-
Dhabi Investment Authority ...,
-
Holdings (Private) Ltd Full...,
-
Program Ii (Co Invest Holdi...,
-
Mark Eisner,
EVP and Chief Medical Officer -
Klaus Frueh,
Director -
Venture Partners Ix, Llcarc...,
-
Kristina Burow,
Director -
Jeffrey S. Hatfield,
Director -
Norbert W Bischofberger,
Director -
Ramy Farid,
Director -
Sung Lee,
EVP & Chief Financial Officer -
Ann M. Hanly,
EVP & Chief Technology Officer -
Backer Marianne De,
Chief Executive Officer